Aruna Railkar

596 total citations
15 papers, 338 citations indexed

About

Aruna Railkar is a scholar working on Molecular Biology, Oncology and Pharmaceutical Science. According to data from OpenAlex, Aruna Railkar has authored 15 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pharmaceutical Science. Recurrent topics in Aruna Railkar's work include Drug Transport and Resistance Mechanisms (3 papers), Drug Solubulity and Delivery Systems (3 papers) and Advanced Drug Delivery Systems (3 papers). Aruna Railkar is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Drug Solubulity and Delivery Systems (3 papers) and Advanced Drug Delivery Systems (3 papers). Aruna Railkar collaborates with scholars based in United States, Switzerland and Finland. Aruna Railkar's co-authors include Navnit H. Shah, Martin H. Infeld, Neil Parrott, Ying Peng, Aki T. Heikkinen, A. Waseem Malick, Saran Kumar, Wantanee Phuapradit, Kin‐Chun Luk and Christine Lukacs and has published in prestigious journals such as Journal of Controlled Release, Journal of Medicinal Chemistry and European Journal of Pharmaceutics and Biopharmaceutics.

In The Last Decade

Aruna Railkar

15 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aruna Railkar United States	11	131	92	61	58	34	15	338
J.D. Pipkin United States	16	175 1.3×	209 2.3×	58 1.0×	34 0.6×	39 1.1×	34	529
Hossein M. Elbadawy Saudi Arabia	13	148 1.1×	58 0.6×	117 1.9×	45 0.8×	34 1.0×	50	570
Sudhanshu Sharma India	11	129 1.0×	57 0.6×	37 0.6×	64 1.1×	34 1.0×	31	416
Haneen A. Basheer Jordan	13	146 1.1×	85 0.9×	51 0.8×	100 1.7×	23 0.7×	28	426
Foyez Mahmud South Korea	12	147 1.1×	51 0.6×	32 0.5×	91 1.6×	47 1.4×	17	332
Hyo-Kyung Han United States	9	191 1.5×	82 0.9×	59 1.0×	177 3.1×	87 2.6×	12	493
Vaibhav Rajoriya India	9	82 0.6×	49 0.5×	66 1.1×	39 0.7×	65 1.9×	22	297
Vivek Makwana Australia	8	235 1.8×	104 1.1×	58 1.0×	42 0.7×	85 2.5×	10	436
Jiexin Deng United States	9	116 0.9×	85 0.9×	31 0.5×	72 1.2×	52 1.5×	14	315
Luka Peternel Slovenia	11	100 0.8×	123 1.3×	26 0.4×	47 0.8×	14 0.4×	21	376

Countries citing papers authored by Aruna Railkar

Since Specialization

Citations

This map shows the geographic impact of Aruna Railkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aruna Railkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aruna Railkar more than expected).

Fields of papers citing papers by Aruna Railkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aruna Railkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aruna Railkar. The network helps show where Aruna Railkar may publish in the future.

Co-authorship network of co-authors of Aruna Railkar

This figure shows the co-authorship network connecting the top 25 collaborators of Aruna Railkar. A scholar is included among the top collaborators of Aruna Railkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aruna Railkar. Aruna Railkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Higgins, Brian, Christian Tovar, Aruna Railkar, et al.. (2015). Abstract A156: Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration. Molecular Cancer Therapeutics. 14(12_Supplement_2). A156–A156. 4 indexed citations

Peng, Ying, et al.. (2014). Applications of a 7-day Caco-2 cell model in drug discovery and development. European Journal of Pharmaceutical Sciences. 56. 120–130. 37 indexed citations

Chen, Yi, Zhi Chen, Romyr Dominique, et al.. (2013). Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(24). 6610–6615. 48 indexed citations

Heikkinen, Aki T., Stephen Fowler, Jia Li, et al.. (2013). In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver. Molecular Pharmaceutics. 10(4). 1388–1399. 18 indexed citations

Sidduri, Achyutharao, Jefferson Tilley, Nadine S. Tare, et al.. (2012). Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4–beta1 and alpha4–beta7 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 23(4). 1026–1031. 5 indexed citations

Tilley, Jefferson, Achyutharao Sidduri, Nadine S. Tare, et al.. (2012). Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 23(4). 1036–1040. 9 indexed citations

Haynes, Nancy-Ellen, Cheryl A. Janson, Jiakui Li, et al.. (2012). Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor. ACS Medicinal Chemistry Letters. 3(9). 764–768. 13 indexed citations

Kolinsky, Kenneth, Christian Tovar, Yue Zhang, et al.. (2011). Preclinical evaluation of the novel multi-targeted agent R1530. Cancer Chemotherapy and Pharmacology. 68(6). 1585–1594. 10 indexed citations

Daouti, Sherif, Brian Higgins, Kenneth Kolinsky, et al.. (2010). Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models. Molecular Cancer Therapeutics. 9(1). 134–144. 23 indexed citations

10.

Haynes, Nancy-Ellen, Wendy L. Corbett, Fred T. Bizzarro, et al.. (2010). Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2R)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). Journal of Medicinal Chemistry. 53(9). 3618–3625. 36 indexed citations

11.

McDermott, Lee, Mary Ellen Simcox, Brian Higgins, et al.. (2005). RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry. 13(16). 4835–4841. 17 indexed citations

12.

Jain, Rajeev, Aruna Railkar, A. Waseem Malick, C. T. Rhodes, & Navnit H. Shah. (1998). Stability of a hydrophobic drug in presence of hydrous and anhydrous lactose. European Journal of Pharmaceutics and Biopharmaceutics. 46(2). 177–182. 7 indexed citations

13.

Shah, Navnit H., et al.. (1996). Effect of processing techniques in controlling the release rate and mechanical strength of hydroxypropyl methylcellulose based hydrogel matrices. European Journal of Pharmaceutics and Biopharmaceutics. 42(3). 183–187. 26 indexed citations

14.

Phuapradit, Wantanee, et al.. (1995). In VitroCharacterization of Polymeric Membrane used for Controlled Release Application. Drug Development and Industrial Pharmacy. 21(8). 955–963. 12 indexed citations

15.

Shah, Navnit H., et al.. (1993). A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers. Journal of Controlled Release. 27(2). 139–147. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact